𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. A Northern California oncology group study

✍ Scribed by Charlotte Jacobs; Frederick Meyers; Charles Hendrickson; Marsha Kohler; Steve Carter

Publisher
John Wiley and Sons
Year
1983
Tongue
English
Weight
500 KB
Volume
52
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II trial of cisplatin and vinore
A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
✍ Enrique Espinosa; Pilar Zamora; Alfredo MillΓ‘; Serafin Morales; Raquel Molina; M πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 75 KB πŸ‘ 2 views

## Abstract ## Objective. We assessed the response rate and the toxicity of cisplatin plus vinorelbine in patients with this condition. ## Patients and Method. Forty‐two patients were included. Therapy consisted of cisplatin, 100 mg/m^2^ on day 1, and vinorelbine, 25 mg/m^2^ on days 1 and 8, giv

Combination chemotherapy with methotrexa
Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck
✍ M. Clavel; F. Cognetti; P. Dodion; J. Wildiers; R. Rosso; A. Rossi; B. Gignoux; πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 449 KB πŸ‘ 2 views

## For the EORTC Head and Neck Cooperative Group A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin, methotrexate, bleomycin, and vincristine (CABO) group received cisplatin (50 mg/m2; day 4), methot